

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI136212

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Partial Termination and Release of Security Interest in Patents		
CONVEYING PARTY DATA			
Name			Execution Date
JPMORGAN CHASE BANK, N.A., as Administrative Agent			03/28/2024
RECEIVING PARTY DATA			
Company Name:	SLAYBACK PHARMA LIMITED LIABILITY COMPANY		
Street Address:	301 Carnegie Center, Suite 303		
City:	Princeton		
State/Country:	NEW JERSEY		
Postal Code:	08540		
PROPERTY NUMBERS Total: 2			
Property Type	Number		
Patent Number:	11766438		
Application Number:	18447620		
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	3129932652		
Email:	heather.poitras@lw.com		
Correspondent Name:	Heather Poitras		
Address Line 1:	c/o Latham & Watkins LLP		
Address Line 2:	330 North Wabash Avenue, Suite 2		
Address Line 4:	Chicago, ILLINOIS 60611		
ATTORNEY DOCKET NUMBER:	049067-0345		
NAME OF SUBMITTER:	Heather Poitras		
SIGNATURE:	Heather Poitras		
DATE SIGNED:	04/03/2024		
Total Attachments: 3			
source=Azurity - Partial Patent Release (Slayback)[Executed]#page1.tif			
source=Azurity - Partial Patent Release (Slayback)[Executed]#page2.tif			
source=Azurity - Partial Patent Release (Slayback)[Executed]#page3.tif			

PARTIAL TERMINATION AND RELEASE OF
SECURITY INTEREST IN PATENTS

This Partial Termination and Release of Security Interest in Patents ("Patent Release") is made as of March 28, 2024, by JPMORGAN CHASE BANK, N.A. ("Administrative Agent") in favor of SLAYBACK PHARMA LIMITED LIABILITY COMPANY, a Delaware limited liability company, with an address at 301 Carnegie Center, Suite 303, Princeton, NJ 08540 (the "Grantor").

W I T N E S S E T H:

WHEREAS, the Grantor has entered into a certain Supplemental Confirmatory Grant of Security Interest in United States Patents, dated September 27, 2023 (the "Patent Security Agreement") with Administrative Agent, notice of which was recorded on September 27, 2023 at the United States Patent and Trademark Office at Reel 065045, Frame 0560.

Capitalized terms used but not otherwise defined herein have the meanings given to them in the Patent Security Agreement.

WHEREAS, the Grantor granted the Administrative Agent, under the terms of the Patent Security Agreement, a continuing security interest (the "Security Interest") in favor of the Administrative Agent, in and to all of the Grantor's right, title and interest in the Patents listed in Schedule A (the "Released Collateral").


WHEREAS, the Administrative Agent has agreed to terminate and release its Security Interest in the Released Collateral as herein provided.

NOW, THEREFORE, in consideration of the foregoing and intending to be legally bound, the Administrative Agent hereby releases, terminates and discharges the Security Interest in the Released Collateral of the Grantor, and assigns, transfers and conveys to Grantor such Security Interest in such intellectual property. For the avoidance of doubt, except as expressly set forth above, nothing herein shall affect the Security Interest held by the Administrative Agent in the other Patents, or any other security interest granted by Grantor or any other grantors to the Administrative Agent.

[Remainder of this page intentionally left blank; signature page follows]

IN WITNESS WHEREOF, the Administrative Agent has caused this Patent Release to be executed as of the day and year first written above.

JPMORGAN CHASE BANK, N.A.,
as Administrative Agent

By: 
Name: David Hyman
Title: Authorized Signor

SCHEDULE A

PATENTS

United States Patents:

OWNER	TITLE	PATENT NUMBER	Grant Date
Slayback Pharma Limited Liability Company	Pharmaceutical compositions of tofacitinib for oral administration	11,766,438	September 26, 2023

United States Patent Applications:

OWNER	TITLE	APPLICATION NUMBER	Application Date
Slayback Pharma Limited Liability Company	Pharmaceutical compositions of tofacitinib for oral administration	18/447,620	August 10, 2023